文献速递肿瘤 PET/CT

癌症免疫环境及其药物干预反应的影像学评估,第一部分:18F-FDG PET/CT的作用

Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18F-FDG PET/CT.
PubMed 文献 · J Nucl Med · 2020-05-22

本综述概述了18F-FDG PET/CT在监测肿瘤及全身免疫反应中的现状。免疫治疗可带来非典型反应模式,挑战影像作为疗效替代指标的框架;全身免疫反应可能破坏健康组织免疫稳态导致不良事件。组织与液体活检受生物学、空间和时间异质性限制,而18F-FDG PET/CT通过解读指南的不断完善和新证据,其在反应评估中的作用正被认识。

要点

  • 免疫治疗可导致非典型反应模式,挑战影像作为疗效可靠替代指标的概念框架。
  • 有效的抗肿瘤反应需要原发和继发淋巴组织中的全身免疫反应,但增强的全身免疫反应可破坏健康组织免疫稳态导致不良事件。
  • 组织与液体活检受限于过程的生物学、空间和时间异质性,而18F-FDG PET/CT通过解读指南的不断完善和新证据,其在反应评估中的作用正被认识。

核心结论

  • 18F-FDG PET/CT作为更广泛可用的反应评估方法,其持续作用正通过解读指南的不断完善和新证据而被认识。
  • 这些无创方法可提供对全身免疫反应生物学基础的洞察,以最大化潜在治疗获益。
  • 本综述旨在概述18F-FDG PET/CT在监测肿瘤和全身免疫反应中的现状, companion综述将讨论其他可能补充18F-FDG PET/CT的影像探针。

研究设计与样本

  • 本文为综述,旨在概述18F-FDG PET/CT在监测肿瘤和全身免疫反应中的现状。

主要发现

  • 免疫治疗药物通过调节肿瘤微环境增强全局免疫反应,但可导致非典型反应模式。
  • 越来越多的证据表明,有效的抗肿瘤反应需要原发和继发淋巴组织中的全身免疫反应。
  • 增强的全身免疫反应可导致健康组织中免疫稳态的破坏,引起不良事件。
  • 组织与液体活检受限于所涉过程的生物学、空间和时间异质性。
  • 使用生物分子对免疫系统细胞特异性谱系标志物进行分子影像的兴趣日益增长。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy agents are now entering the clinic in a wide array of malignancies and have provided a valuable addition to the therapeutic armamentarium. These agents enhance the global immune response by modulating the tumor microenvironment but can lead to unconventional patterns of response, challenging the conceptual framework that imaging is a robust surrogate for therapeutic efficacy. There is also increasing evidence that an effective antitumor response requires a systemic immune response in primary and secondary lymphoid tissues. However, an enhanced systemic immune response can lead to disruption of immunologic hemostasis in healthy tissues, causing adverse events. Better understanding of the complex interplay between tumoral and systemic immune response has been provided through tissue and liquid biopsy. However, the applicability of these methods is constrained by the biologic, spatial, and temporal heterogeneity of the processes involved. There is a growing interest in molecular imaging of cell-specific lineage markers of the immune system using biomolecules. However, the ongoing role of the more widely available 18F-FDG PET/CT for response assessment is being recognized through ongoing refinement of interpretative guidelines and emerging evidence. These noninvasive methods provide insights into the biologic basis of the global immune response to maximize potential therapeutic benefit. In this review, we aim to provide an overview of the current status of 18F-FDG PET/CT in the monitoring of tumoral and systemic immune response. In a companion review, the role of other imaging probes that might complement 18F-FDG PET/CT will be discussed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Iravani A, Hicks RJ. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18F-FDG PET/CT. J Nucl Med. 2020. PMID: 32444375. doi:10.2967/jnumed.119.234278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。